Our global pharmaceutical client had an immunotherapy in early-stage clinical development. It engaged Prescient to provide impactful insights for its drug’s early clinical development strategy by analyzing immunotherapy competitors’ clinical development strategies, including patient segmentation, indication sequencing and regulatory strategies; to predict competitors’ data read-out timings, development timelines, registrational strategies, and safety and efficacy data; and to provide insights into the evolution of the standard of care.

Shaping Decisions | Driving Value

Prescient began the engagement by analyzing all of the clinical trial designs of the immunotherapy competitors. We grouped the trials by disease, setting or phase to decipher clinical development progressions and the choices competitors made during development. Next, we performed in-depth analysis of all the competitors’ clinical data and comparative analyses with the client’s drug. We interviewed KOLs regarding clinical development strategies and clinical data to support the secondary analysis. Finally, we performed due diligence on treatment paradigms, gathered insights into the evolving standard of care as immunotherapy products came to the market, predicted competitors’ development strategies, and recommended clinical and regulatory strategies for the client’s product.

The Prescient Advantage

Because of the ongoing nature of the engagement, the client was able to constantly update its brand team on the changes in the competitor landscape of this extremely fast-moving field. The comparative analysis of clinical trial designs and clinical data provided the team with up-to-date insights that enabled it to identify opportunities, modify strategy, differentiate from the competitors, and develop a clinical strategy that delivered a competitive edge despite being third or fourth to market.